WO2010139979A3 - Procédés d'élaboration de formes cristallines - Google Patents

Procédés d'élaboration de formes cristallines Download PDF

Info

Publication number
WO2010139979A3
WO2010139979A3 PCT/GB2010/050892 GB2010050892W WO2010139979A3 WO 2010139979 A3 WO2010139979 A3 WO 2010139979A3 GB 2010050892 W GB2010050892 W GB 2010050892W WO 2010139979 A3 WO2010139979 A3 WO 2010139979A3
Authority
WO
WIPO (PCT)
Prior art keywords
dasatinib
processes
crystalline forms
preparing crystalline
relates
Prior art date
Application number
PCT/GB2010/050892
Other languages
English (en)
Other versions
WO2010139979A2 (fr
Inventor
Vinayak Govind Gore
Laxmikant Patkar
Amit Bagul
Priyesh Surendra Vijaykar
Mahesh Edake
Original Assignee
Generics [Uk] Limited
Mylan India Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics [Uk] Limited, Mylan India Private Limited filed Critical Generics [Uk] Limited
Publication of WO2010139979A2 publication Critical patent/WO2010139979A2/fr
Publication of WO2010139979A3 publication Critical patent/WO2010139979A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

L'invention concerne des intermédiaires et leur élaboration, aux fins d'utilisation dans la fabrication de dasatinib pur, en particulier le monohydrate de dasatinib et le dasatinib anhydre. L'invention concerne aussi des compositions pharmaceutiques renfermant du dasatinib pur et leur utilisation dans le traitement du cancer.
PCT/GB2010/050892 2009-06-03 2010-05-28 Procédés d'élaboration de formes cristallines WO2010139979A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN828KO2009 2009-06-03
IN828/KOL/2009 2009-06-03
IN829/KOL/2009 2009-06-03
IN829KO2009 2009-06-03

Publications (2)

Publication Number Publication Date
WO2010139979A2 WO2010139979A2 (fr) 2010-12-09
WO2010139979A3 true WO2010139979A3 (fr) 2011-05-05

Family

ID=42734619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/050892 WO2010139979A2 (fr) 2009-06-03 2010-05-28 Procédés d'élaboration de formes cristallines

Country Status (1)

Country Link
WO (1) WO2010139979A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101891738B (zh) * 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 达沙替尼多晶型物及其制备方法和药用组合物
CN102898424A (zh) * 2011-07-29 2013-01-30 江苏奥赛康药业股份有限公司 达沙替尼新的多晶型物及其制备方法
WO2013065063A1 (fr) 2011-11-03 2013-05-10 Cadila Healthcare Limited Forme anhydre du dasatinib, son procédé de préparation et son utilisation
CN102408423B (zh) * 2011-11-29 2013-12-25 上海希迪制药有限公司 一种制备大粒径达沙替尼的方法
WO2013078973A1 (fr) * 2011-11-29 2013-06-06 上海创诺制药有限公司 Dasatinib à grand diamètre des particules et sa préparation et son utilisation
NZ630288A (en) * 2012-04-20 2015-08-28 Shilpa Medicare Ltd Process for preparing dasatinib monohydrate
CN103709156B (zh) * 2012-09-29 2016-08-03 石药集团中奇制药技术（石家庄）有限公司 一种达沙替尼多晶型药物及其制备方法
CZ306598B6 (cs) * 2012-12-06 2017-03-22 Zentiva, K.S. Způsob přípravy a čištění nových i známých polymorfů a solvátů dasatinibu
CN103408542B (zh) * 2013-08-13 2016-06-29 南京优科生物医药研究有限公司 一种高纯度的达沙替尼无水物的制备方法
IN2013MU03610A (fr) * 2013-12-18 2015-04-24 Dharmesh Mahendrabhai Shah
US9168226B1 (en) 2015-08-07 2015-10-27 David Wong Injectable particle
US10800771B2 (en) 2016-12-01 2020-10-13 Natco Pharma Limited Process for the preparation of dasatinib polymorph
WO2019209908A1 (fr) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Formes cristallines de dasatinib
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004067A1 (en) * 2004-02-06 2006-01-05 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2009053854A2 (fr) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphes de dasatinib et leur procédé de préparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937270A1 (fr) 2005-09-21 2008-07-02 Brystol-Myers Squibb Company Administration par voie orale de n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide et sels de celui-ci

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004067A1 (en) * 2004-02-06 2006-01-05 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
WO2009053854A2 (fr) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphes de dasatinib et leur procédé de préparation

Also Published As

Publication number Publication date
WO2010139979A2 (fr) 2010-12-09

Similar Documents

Publication Publication Date Title
WO2010139979A3 (fr) Procédés d'élaboration de formes cristallines
WO2010092090A3 (fr) Nouveaux sels de la sitagliptine
WO2010139981A3 (fr) Procédés d'élaboration de formes cristallines
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
IL214396A (en) Anti-viral anti-viral nucleosides, pharmaceutical preparations containing them and methods for their preparation, as well as their preparation of antiviral intermediates
WO2011130615A3 (fr) Synthèse de lacosamide
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2011060049A3 (fr) Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2
WO2011017502A3 (fr) Formulations comprenant du linaclotide
IN2012DN03182A (fr)
EP2431366A4 (fr) Nouveau composé conjugué de chlore e6-acide folique, procédé de préparation de ce composé et composition pharmaceutique contenant ledit composé pour le traitement du cancer
WO2010150211A3 (fr) Utilisation de dérivés d'indoles dans le traitement du cancer
PL2429507T3 (pl) Kompozycja farmaceutyczna wolna od fosforanów do leczenia jaskry
WO2011006935A3 (fr) Dérivés de tétrazole
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
WO2011069032A3 (fr) Formulations, sels et polymorphes de la transnorsertraline, et leurs utilisations
WO2010079045A3 (fr) Nouveaux sels
WO2010006904A3 (fr) Nouvelles formes cristallines du rabéprazole sodique
IN2013DN02555A (fr)
WO2010131035A8 (fr) Nouveau polymorphe cristallin du dihydrogénophosphate de sitagliptine
WO2010061220A3 (fr) Nouveaux procédés et polymorphes purs
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
WO2011095985A3 (fr) Sels de rasagiline et procédés de preparation de ces derniers
WO2010146595A3 (fr) Nouveaux polymorphes d'hydrochlorure de flibansérine
WO2011027359A3 (fr) Nouveau procédé de préparation de 4-hydroxy atomoxétine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10722771

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10722771

Country of ref document: EP

Kind code of ref document: A2